Shares of newly public Metsera (NASDAQ:MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a $275M initial public offering. Metsera (NASDAQ:MTSR) shares opened at $25 ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Odyssey Therapeutics and Sionna Therapeutics have filed to carry out initial public offerings (IPOs ... in the footsteps of obesity drug developer Metsera and genetic medicines developer Maze ...

In February, Metsera completed an IPO ... in professional and consulting fees as we prepared for our initial public offering and an increase in personnel-related expenses as we expanded our ...

Shares of up-and-coming weight loss drug developers Viking Therapeutics (NASDAQ:VKTX), Metsera (NASDAQ:MTSR), and Structure Therapeutics (NASDAQ:GPCR) traded sharply higher after Pfizer (NYSE ...

In February, Metsera completed an IPO ... in professional and consulting fees as we prepared for our initial public offering and an increase in personnel-related expenses as we expanded our ...